The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
To meet the demands of increasingly complex medicinal products, technologies like mass spectrometry are needed – also in a QC lab. However, for methods like MAM by LC-MS and HCP by MS little experience on how to handle mass spectrometry in a QC lab is currently available. Emerging new technologies (currently used during characterisation of new therapeutic drug modalities) as release testing methods are discussed in this session.
Session Speakers: Regulatory Considerations for the Application of Multi-attribute Method by Mass Spectrometry for QC Release and Stability Testing of Biopharmaceuticals Annick Gervais, representing EFPIA, Belgium
A Status Report from the MAM Implementation Phase Alexander Buettner, Roche Diagnostics GmbH, Germany
A Roadmap to Get Host Cell Protein Analysis by Mass Spectrometry in a GMP Environment Cyrille Chéry, UCB Pharma SA, Belgium
Novel HCP Analysis and Characterisation Tools Provide Freedom of Operation for Efficient Process Development Brian Kåre Kristensen, Novo Nordisk A/SA, Denmark